Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Liver Cancer

 

ADI-PEG 20 for Advanced Hepatocellular Carcinoma (20120106)
POLARIS2009-001: A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy

Investigator: William P. Harris, MD;   Conditions: Liver Cancer;    Status: Recruiting;   Study ID: NCT01287585

TheraSphere for Inoperable Liver Cancer (20111617)
A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)

Investigator: William Harris;   Conditions: Gastrointestinal Cancer; Liver Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01556490

Tivantinib (ARQ 197) for Hepatocellular Carcinoma (13017)
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy

Investigator: William P. Harris, MD;   Conditions: Hepatocellular Carcinoma;    Status: Recruiting;   Study ID: NCT01755767

Lenvatinib (E7080) Vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (20131240)
A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Investigator: William Harris;   Conditions: Hepatocellular Carcinoma;    Status: Recruiting;   Study ID: NCT01761266

Cabozantinib (XL184) in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib (20130857)
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Investigator: William Harris;   Conditions: Hepatocellular Carcinoma;    Status: Recruiting;   Study ID: NCT01908426

ADI PEG 20 Plus Sorafenib for Advanced Hepatocellular Carcinoma
A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Investigator: William P. Harris, MD;   Conditions: Hepatocellular Carcinoma;    Status: Recruiting;   Study ID: NCT02101593